Loading
Choose a cancer type (or all), switch between products, technologies, targets, trials, pairings, ideas, companies, and institutions, then sort and filter. Every row links to its page. The rank is a disclosed documentation-and-evidence score, not a measure of clinical benefit.
| # | Why it ranks | |||||
|---|---|---|---|---|---|---|
| 1 | Abemaciclib Small-molecule CDK4/6 inhibitor · Abemaciclib was the first CDK4/6 inhibitor approved after surgery for high-risk hormone-positive breast cancer. | Approved2017🇺🇸🇪🇺🇬🇧🇯🇵+2 | evidence + links | 112 | 2021 | 20 |
| 2 | Abiraterone acetate Small-molecule CYP17A1 inhibitor · Abiraterone is a pill that shuts down testosterone production everywhere, including inside the tumour. Discovered at the Institute of Cancer Research, now generic and used from the first metastatic diagnosis. | Approved2011🇺🇸🇪🇺🇬🇧🇯🇵+3 | evidence + links | 138 | 2018 | 20 |
| 3 | Acalabrutinib Small-molecule covalent BTK inhibitor (second generation) · Acalabrutinib is a cleaner BTK blocker with fewer heart and bleeding problems than ibrutinib. In February 2026 it became half of the first all-oral, fixed-duration CLL regimen approved in the United States. | Approved2017🇺🇸🇪🇺🇬🇧🇯🇵+2 | evidence + links | 98 | 2026 | 20 |
| 4 | Adagrasib Small-molecule inhibitor (KRAS G12C) · Adagrasib was the second KRAS G12C inhibitor, with a long half-life and brain penetration, and is approved in lung cancer. Its US approval with cetuximab in colorectal cancer was removed in August 2026. | Approved2022🇺🇸🇪🇺🇬🇧🇦🇺 | evidence + links | 79 | 2024 | 20 |
| 5 | Adebrelimab Monoclonal antibody (anti-PD-L1, humanised IgG4) · Adebrelimab is Hengrui's PD-L1 antibody, approved in China for first-line extensive-stage small cell lung cancer on the CAPSTONE-1 trial. | Approved2023🇨🇳 | evidence + links | 126 | 2023 | 20 |
| 6 | Afamitresgene autoleucel TCR-T (MAGE-A4) · Afamitresgene autoleucel was the first engineered T-cell receptor therapy approved for a solid tumour, synovial sarcoma. | Approved2024🇺🇸 | evidence + links | 34 | 2024 | 20 |
| 7 | Afatinib Small-molecule pan-ErbB TKI (second generation, irreversible) · Afatinib (Gilotrif) is a second-generation pill that binds EGFR, HER2 and HER4 irreversibly, approved in 2013 for EGFR-mutant lung cancer. Its lasting value is activity against the uncommon EGFR mutations G719X, L861Q and S768I, approved in 2018, because osimertinib has displaced it for common mutations and its wild-type EGFR binding causes more rash and diarrhoea. | Approved2013🇺🇸🇪🇺🇬🇧🇯🇵+2 | evidence + links | 39 | 2018 | 20 |
| 8 | Aldesleukin (high-dose IL-2) Recombinant interleukin-2 (cytokine) · High-dose interleukin-2 was the first immunotherapy to cure a small fraction of patients with metastatic melanoma and kidney cancer, at the cost of ICU-level toxicity; today it mainly supports TIL therapy. | Approved1992🇺🇸🇪🇺🇬🇧🇦🇺 | evidence + links | 39 | 1998 | 20 |
| 9 | Alectinib Small-molecule kinase inhibitor (ALK) · Alectinib is a well-tolerated ALK pill, standard first line for years and, since 2024, the first targeted therapy given after surgery for ALK-positive lung cancer. | Approved2014🇺🇸🇪🇺🇬🇧🇯🇵+2 | evidence + links | 72 | 2024 | 20 |
| 10 | Alemtuzumab Monoclonal antibody (anti-CD52) · Alemtuzumab (Campath) is an antibody that wipes out lymphocytes carrying the CD52 marker. It is approved for chronic lymphocytic leukaemia and is supplied in the US through a restricted distribution programme. | Approved | evidence + links | 23 | 2001 | 20 |
| 11 | Alpelisib Small-molecule PI3Kα inhibitor · Alpelisib was the first PI3K drug for PIK3CA-mutant breast cancer (2019). It is effective, but high blood sugar and rash limited its use, and newer drugs for the same pathway have since been approved. | Approved2019🇺🇸🇪🇺🇬🇧🇨🇳+1 | evidence + links | 53 | 2019 | 20 |
| 12 | Aminolevulinic acid (topical, for photodynamic therapy) Topical porphyrin precursor for photodynamic therapy · Aminolevulinic acid is painted on sun-damaged skin and then activated with a lamp, destroying actinic keratoses before they can become skin cancer; the gel is also approved for superficial basal cell carcinoma, in Europe and, since September 2026, in the US. | Approved | evidence + links | 23 | 2026 | 20 |
| 13 | Amivantamab Bispecific antibody (EGFR×MET) · A two-armed antibody that blocks EGFR and its escape partner MET, now first-line for EGFR-mutant lung cancer with lazertinib. | Approved2021🇺🇸🇪🇺🇬🇧🇯🇵+2 | evidence + links | 102 | 2026 | 20 |
| 14 | Anastrozole Oral non-steroidal aromatase inhibitor · Anastrozole is a daily tablet that stops the body making oestrogen after the menopause. It treats and prevents hormone-receptor-positive breast cancer and is an alternative to tamoxifen after surgery for ductal carcinoma in situ. | Approved | evidence + links | 32 | 2002 | 20 |
| 15 | Anlotinib Small-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR, KIT) · Anlotinib is one of the most used cancer pills in China, first approved for lung cancer after other treatments have failed and then for several rarer tumours. | Approved2018🇨🇳 | evidence + links | 53 | 2021 | 20 |
| 16 | Apalutamide Small-molecule AR antagonist · An AR blocker approved for prostate cancer that has spread and for high-risk disease before it shows on scans. | Approved2018🇺🇸🇪🇺🇬🇧🇯🇵+2 | evidence + links | 56 | 2019 | 20 |
| 17 | Apixaban Direct oral anticoagulant (factor Xa inhibitor, tablet) · Apixaban is a blood-thinning tablet. Guidelines now accept it for treating a clot in most people with cancer, and for preventing clots in some people starting chemotherapy who are at higher risk. | Approved | evidence + links | 21 | 2012 | 20 |
| 18 | Aprepitant (and fosaprepitant) Neurokinin-1 receptor antagonist (antiemetic) · Aprepitant (Emend) was the first of a new class of anti-sickness drugs. Taken with a 5-HT3 blocker and dexamethasone, it prevents the delayed nausea and vomiting that follow strongly emetogenic chemotherapy such as cisplatin. | Approved2003🇪🇺 | evidence + links | 20 | 2008 | 20 |
| 19 | Arsenic trioxide Inorganic arsenical (differentiation agent) · An ancient poison turned cure: with retinoic acid it cures more than 95% of acute promyelocytic leukaemia without conventional chemotherapy. | Approved2000🇺🇸🇪🇺🇬🇧🇯🇵+2 | evidence + links | 34 | 2018 | 20 |
| 20 | ArteraAI Prostate AI digital pathology prognostic/predictive test · The first AI tool cleared by the FDA to predict both prognosis and treatment benefit from a routine biopsy slide, in prostate cancer. | Approved2025🇺🇸 | evidence + links | 26 | 2025 | 20 |
| 21 | Asciminib Small-molecule allosteric ABL1 inhibitor (STAMP) · Asciminib is a BCR::ABL1 blocker that binds a different pocket from every other approved TKI, given accelerated approval for newly diagnosed chronic-phase chronic myeloid leukaemia in 2024 and now being tested in Ph-positive ALL. | Approved2021🇺🇸🇪🇺🇬🇧🇯🇵+2 | evidence + links | 51 | 2024 | 20 |
| 22 | Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase) Enzyme therapy · An enzyme that starves leukaemia cells of an amino acid they cannot make; a mainstay of childhood ALL therapy for 50 years, with new versions solving allergy and supply problems. | Approved1994🇺🇸🇪🇺🇬🇧🇯🇵+2 | evidence + links | 42 | 2021 | 20 |
| 23 | Atezolizumab Monoclonal antibody (anti-PD-L1) · A PD-L1 blocker used in lung, liver, and bladder cancer. In 2026 it became the first drug approved based on a blood test showing leftover cancer after bladder surgery. | Approved2016🇺🇸🇪🇺🇬🇧🇯🇵+2 | evidence + links | 338 | 2026 | 20 |
| 24 | Aumolertinib Small-molecule third-generation EGFR TKI · Aumolertinib is Hansoh's third-generation lung cancer pill, the first China-developed drug of its class, approved for first-line EGFR-mutant lung cancer on the AENEAS trial. | Approved2020🇨🇳 | evidence + links | 24 | 2021 | 20 |
| 25 | Avapritinib Small-molecule kinase inhibitor (PDGFRA D842V / KIT) · Avapritinib is the first drug for GIST driven by the PDGFRA D842V mutation, which resists every other kinase inhibitor; it is also approved for systemic mastocytosis. | Approved2020🇺🇸🇪🇺🇬🇧🇨🇳+1 | evidence + links | 56 | 2021 | 20 |
| 26 | Avelumab Monoclonal antibody (anti-PD-L1) · Avelumab is a PD-L1 blocker given as maintenance after chemotherapy for advanced bladder cancer, which lengthened survival by about seven months. | Approved2017🇺🇸🇪🇺🇬🇧🇯🇵+2 | evidence + links | 89 | 2020 | 20 |
| 27 | Avutometinib + defactinib Small-molecule RAF/MEK clamp + FAK inhibitor · Avutometinib plus defactinib is the first treatment approved specifically for low-grade serous ovarian cancer, a slow-growing type driven by the RAS pathway. | Approved2025🇺🇸 | evidence + links | 25 | 2025 | 20 |
| 28 | Axicabtagene ciloleucel CAR-T (CD19) · A CD19 CAR-T after which about 40% of patients with large B-cell lymphoma who had failed everything were alive five years later, and which beat transplant in second line. | Approved2017🇺🇸🇪🇺🇬🇧🇯🇵+2 | evidence + links | 79 | 2022 | 20 |
| 29 | Axitinib Small-molecule kinase inhibitor (VEGFR) · Axitinib is a selective VEGF-receptor pill, now given mainly with pembrolizumab or avelumab as first-line kidney cancer treatment. | Approved2012🇺🇸🇪🇺🇬🇧🇯🇵+2 | evidence + links | 42 | 2019 | 20 |
| 30 | Azacitidine Small-molecule hypomethylating agent (cytotoxic) · A gentle chemotherapy that switches silenced genes back on. With venetoclax it became the standard for older people with AML who cannot take intensive treatment. | Approved2004🇺🇸🇪🇺🇬🇧🇯🇵+2 | evidence + links | 154 | 2020 | 20 |
For a chosen cancer: standard-of-care mention +40, in its pipeline +25, in its history +10, directly linked +15, linked through one of its drugs +5. Always: evidence tier (approved 10 … concept 0) plus half a point per connection in the graph, capped at 10. With Personalise on: a match to one of your biomarkers +20, approval in your region +10, a standard-of-care setting matching your stage +15. It ranks documentation and evidence, not clinical benefit.